Immuneering GAAP EPS of -$0.18 beats by $0.13
Source: SeekingAlpha
2026-03-06 08:02:09 ET
More on Immuneering
- Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data
- Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript
- Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3
- Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer
- Immuneering to be added to the Nasdaq Biotechnology Index
Read the full article on Seeking Alpha
For further details see:
Immuneering GAAP EPS of -$0.18 beats by $0.13
Immuneering Corporation
NASDAQ: IMRX
IMRX Trading
4.57% G/L:
$5.15 Last:
437,998 Volume:
$4.85 Open:
IMRX Latest News
March 06, 2026 07:45:00 am
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
February 18, 2026 04:05:00 pm
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
IMRX Stock Data
$324,141,234
49,783,445
3.08%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
